Transforming kidney transplant monitoring with urine CXCL9 and CXCL10: practical clinical implementation
Authors:
Open Access
- 2 September 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Abstract
In kidney transplant recipients, urine CXCL9 and CXCL10 (uCXCL9/10) chemokines have reached a sufficiently high level of evidence to be recommended by the European Society of Organ Transplantation for the monitoring of immune quiescence. To assess the risk of acute rejection (AR), the advantage of uCXCL9/10 is their cost-effectiveness and their high diagnostic performance. Here, we evaluated the feasibility of a next-generation immunoassay for quantifying uCXCL9/10 levels. It demonstrated high efficiency with minimal workflow and a 90-min time to result. Preanalytical studies indicated stability of uCXCL9/10 levels and analytical studies confirmed excellent linearity and precision. In a cohort of 1048 samples collected at biopsy, the results correlated significantly with ELISA quantification and were integrated into a previously validated 8-parameter urine chemokine model. The next generation immunoassay achieved an accuracy of 0.84 for AR diagnosis. This study validates this technology as a robust, locally available and unexpensive platform and marks a significant step towards the widespread implementation of uCXCL9/10, for immune quiescence monitoring. Therefore, we developed an open-access web application using uCXCL9/10 to calculate AR risk and improve clinical decision-making to perform biopsy, ushering in a new era in kidney transplantation, where personalized, data-driven care becomes the norm.Keywords
Funding Information
- Société Francophone de Transplantation
- Emmanuel Boussard Foundation
- Day Solvay Foundation
This publication has 27 references indexed in Scilit:
- Automated Urinary Chemokine Assays for Noninvasive Detection of Kidney Transplant Rejection: A Prospective Cohort StudyAmerican Journal of Kidney Diseases, 2023
- Modulation of Monocyte Response by MicroRNA-15b/106a/374a During Antibody-mediated Rejection in Kidney TransplantationTransplantation, 2022
- Biological pathways and comparison with biopsy signals and cellular origin of peripheral blood transcriptomic profiles during kidney allograft pathologyKidney International, 2022
- A Practical Guide to the Clinical Implementation of Biomarkers for Subclinical Rejection Following Kidney TransplantationTransplantation, 2020
- Urinary CXCL10 Chemokine Is Associated With Alloimmune and Virus Compartment-Specific Renal Allograft InflammationTransplantation, 2018
- Establishing Biomarkers in Transplant MedicineTransplantation, 2016
- Multicenter Validation of Urinary CXCL9 as a Risk-Stratifying Biomarker for Kidney Transplant InjuryAmerican Journal of Transplantation, 2013
- Urinary-Cell mRNA Profile and Acute Cellular Rejection in Kidney AllograftsNew England Journal of Medicine, 2013
- Immune monitoring and biomarkers to predict chronic allograft dysfunctionKidney International, 2010
- Taking a new biomarker into routine use – A perspective from the routine clinical biochemistry laboratoryProteomics – Clinical Applications, 2010